DRIO offering diabetes monitoring solution utilizing smartphones
buzzstockslive Newsletter
Trouble with this email Click me http://campaign.r20.constantcontact.com/rendercacc44d2-6eb8-416e-8c69-50cdf6b2e836&c=c9179ec0-b5c5-11e3-a215-d4ae5292c4bc&ch=c9fcf5b0-b5c5-11e3-a265-d4ae5292c4bc LabStyle Innovations Corp. (DRIO) ~~~~~~~~~~~~~~~~~~~~~~~~~~
LabStyle Innovations Corp. (DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices.
Overview of flagship product DRIO`s flagship product is the Dario personalized Diabetes mHealth Solution. Dario received CE mark certification in September 2013 and began a world rollout of the Dario mobile application in select countries in December 2013, and initial launches of the full Dario solution have commenced in Europe, Australia and New Zealand during 2014.
DRIO also filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario smart meter (Dario(TM) Blood Glucose Monitoring System) in December 2013, according to a May 22 press release.
The company is also pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services, and in April 2014 DRIO received a Notice of Allowance for a U.S. patent covering core functions of the Dario Blood Glucose Monitoring System, the May 22 press release stated.
Check out this video of how the product works: http://www.mydario.com/ .
DRIO highlights recent achievements and outlines key milestones for 2014 Earlier this month, DRIO outlined some of its achievements for the first few months of 2014, and outlined some of its key milestones for the remainder of the year.
Among the company`s key highlights were: commencing first shipments of the Dario Diabetes Management Solution to distributors in Italy, New Zealand and the United Kingdom, collecting initial positive feedback; receiving a Notice of Allowance from the U.S. Patent and Trademark Office for core patent claims covering the Dario Personalized Smart Meter, which works in tandem with the novel and powerful Dario software application to form the overall Dario Diabetes Management Solution; working with FDA towards potential clearance of the Dario Personalized Smart Meter in the U.S. following a 510K filing made in late December 2013; and raising $3.8M in net proceeds from private placement which had its closing on February 2014.
Key goals for the remainder of the year, which were outlined in a May 15 press release included: expediting production of Dario Personalized Smart Meters in selected jurisdictions with maximum optimization and efficiency; continuing to enhance logistics and shipment process in order to ship and deliver Dario Personalized Smart Meters and test strips in a timely and productive manner; expanding distributor network with purchase commitments in strategic markets; increasing awareness of Dario and sales penetration in key target markets; and obtaining 510K FDA clearance for the Dario personalized smart meter by the end of 2014.
“It was a very exciting quarter for LabStyle,” said DRIO`s president and CEO Erez Raphael, in the May 15 press release. “We closed the quarter with first shipments of Dario to distributers in Italy, New Zealand and the United Kingdom and we already received positive feedback from both our distribution partners and end-users. Compared to the fourth quarter of 2013, our marketing and pre-production expenses have increased, as we prepared for the soft launch that began in March 2014, and we have reduced our research and development expenses and general and administrative spending during this quarter in order to preserve and focus resources for our ongoing commercialization efforts.” To learn more about DRIO, visit: http://www.mydario.com/
Disclaimer:
Do not base any inv est ment decision upon any of the materials found in this publication or on our Web site.
The information contained on our website or in any of our newsletters is for informational purposes only, and is not intended to be advice, nor a recommendation and/or guidance for investment decisions. In preparing this publication, we have relied upon information supplied by public information, and press releases which we believe to be reliable; however, such reliability cannot be guaranteed, nor is it verified by us. We are engaged in the business of profiling companies for monetary compensation. All direct and third party comp ensation received has been disclosed on our newsletter and/or our website in accordance with section 1 7 (b) of the Sec uri ties A c t of 1 9 3 3.
Compe nsation: We have not been co m pensat ed for this publication. We do not own any shares of LabStyle Innovations Corp.
~~~~~~~~~~~~~~~~~~~~~~~~~~
~~~~~~~~~~~~~~~~~~~~~~~~~~
Forward this email
Related posts: